Clinical trials: sponsored by Hoffmann-La Roche
Healthy Volunteers
Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects
This was a single-center, multiple-dose, randomized, double-blind, placebo-controlled, positive-controlled, twelve sequence, 3-period cross-over study to investigate the effect of balovaptan on the QTc interval in healthy…
- Trial name
- NCT03808298
- Testing
- Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD 2 (NCT03114657)
- Testing
- Crenezumab
- Where
- 211 sites in United States, Argentina and 25 more
- Volunteers
- 806 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate…
- Trial name
- CREAD OLE (NCT03491150)
- Testing
- Crenezumab
- Where
- 66 sites in United States, Australia and 14 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Healthy Participants
A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.
To evaluate the safety and tolerability of single and multiple ascending doses of oral RO7020531 in Chinese healthy participants.
- Trial name
- NCT03530917
- Testing
- RO7020531
- Where
- Hong Kong
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone…
- Trial name
- NCT02055820
- Testing
- Venetoclax, Cyclophosphamide, Obinutuzumab
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants
This is a two-part, open-label, healthy volunteer study. Part I will investigate the relative bioavailability of capsule and tablet formulations of RO7017773.
- Trial name
- NCT03847987
- Testing
- RO7017773 Phase I Capsule, RO7017773 Phase II Tablet Unflavored, RO7017773 Phase II Tablet Sweetened/Flavored
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
This is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R/R FL and rituximab in combination with…
- Trial name
- NCT02624986
- Testing
- Idasanutlin, Obinutuzumab, Rituximab
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice
This prospective, multicenter, observational study will evaluate the use of concomitant glucocorticoid therapy in adults with rheumatoid arthritis (RA) being treated with tocilizumab in daily clinical practice.
- Trial name
- COGNOS (NCT03291457)
- Testing
- Tocilizumab, Glucocorticoid Agent
- Where
- 22 sites in Belgium
- Volunteers
- 101 people
- Sponsor
- Hoffmann-La Roche
Solid Cancers
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies.
- Trial name
- NCT02174172
- Testing
- Atezolizumab, Bevacizumab, Interferon alfa-2b
- Where
- 9 sites in United States, Netherlands
- Volunteers
- 158 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants
The purpose of this study is to investigate the effect of multiple oral doses of itraconazole on the pharmacokinetics of RO7017773 in healthy volunteers.
- Trial name
- NCT03774576
- Testing
- RO7017773, Itraconazole
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with…
- Trial name
- NCT03629184
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- 37 sites in United States, Costa Rica and 5 more
- Volunteers
- 173 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndromes
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
This is a Phase IV, prospective, multi-center, open-label study to assess the effectiveness and safety profile of epoetin beta (Recormon®) for treatment of symptomatic anemia in adult participants associated with…
- Trial name
- NCT02145026
- Testing
- Epoetin beta
- Where
- 10 sites in Thailand
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics of intravenous (IV) dosing of atezolizumab in combination with oral erlotinib or alectinib in participants with NSCLC.
- Trial name
- NCT02013219
- Testing
- Alectinib, Atezolizumab, Erlotinib
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Study BP29541 is a first-in-human, open-label, multi-center, dose-escalation Phase I clinical study of single-agent RO6958688 in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA) positive solid…
- Trial name
- NCT02324257
- Testing
- RO6958688, Obinutuzumab, Tocilizumab
- Where
- 21 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina
This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina.
- Trial name
- NCT03059251
- Testing
- Obinutuzumab
- Where
- 3 sites in Argentina
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Advanced/Metastatic Solid Tumors
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to…
- Trial name
- NCT02665416
- Testing
- Selicrelumab, Vanucizumab, Bevacizumab
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 94 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT01507168
- Testing
- GC33
- Where
- 57 sites in United States, Belgium and 11 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Glaucoma, Open-angle, Ocular Hypertension
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and…
- Trial name
- NCT03293992
- Testing
- 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche